The Board has approved standalone Quarterly and Half Yearly Results ended 30th September,2025 along with Auditor Report thereon.
Awaiting price reaction for this filing.
Blueblood Ventures Ltd's board approved its unaudited standalone results for Q2 and H1 FY26 (ended 30 September 2025), reviewed by auditor KRA & Associates with an unmodified opinion. Revenue from operations jumped sharply to Rs 100.79 lakhs from Rs 17.94 lakhs in the same period last year (~5.6x growth), while total revenue rose to Rs 110.40 lakhs. The company swung back to a profit of Rs 16.98 lakhs versus a small loss of Rs 0.23 lakhs in H1 FY25, with EPS at Rs 0.57. However, other expenses ballooned to Rs 90.25 lakhs from Rs 5.51 lakhs, and operating cash flow remained deeply negative at Rs (491.69) lakhs. The auditor flagged an emphasis of matter around 247 ZOCDs (worth Rs 247 lakhs) wrongly transferred to a party, unrecovered long-term loans and advances of Rs 6,188.55 lakhs, and a pending service tax settlement under the SVLDRS scheme.
The return to profitability and strong revenue growth are positives, but the spike in other expenses, negative operating cash flow, and large unrecovered advances raise concerns about earnings quality and asset recoverability. Shareholders should watch whether management can recover the misplaced ZOCDs and the Rs 6,188.55 lakhs in long-term advances.